Avicenna.AI, a Marsille, Frace-based medical imaging AI firm, raised $10M in Sequence A funding.
The spherical was led by Innovacom and CEMAG Make investments.
The corporate intends to make use of the funds to scale up deployment of its options internationally and to diversify its providing into new areas of medication.
Co-founded by Cyril Di Grandi, and Dr. Peter Chang, Avicenna.AI supplies healthcare AI options that use deep studying to determine, detect and quantify life-threatening pathologies from CT medical photos. Utilizing a mixture of deep studying and machine studying applied sciences, the corporate’s options robotically detect and prioritize emergency instances inside seconds, and assess them for severity, earlier than alerting radiologists.
The corporate’s enterprise mannequin relies on an asset-light, R&D powerhouse experience, producing fast enterprise development potential via already signed business partnerships with main market actors within the US, Europe and Asia.
2022 noticed Avicenna’s AI options rolled out to greater than 140 hospitals in 14 international locations throughout three continents. The corporate is now able to scale up in 2023 and expects to deploy no less than 30 new websites each month this yr.
In parallel, Avicenna’s R&D efforts will add to the 4 FDA and 6 CE mark approvals already awarded to its merchandise. The corporate’s FDA-cleared and CE-Marked instruments for neurovascular and thoraco-abdominal pathologies are built-in throughout the scientific workflow, robotically triggering and reporting algorithm outcomes via the techniques already utilized by radiologists.
FinSMEs
08/02/2023
